Zofran: Applications in Medicine as a Serotonin Blocker
Chemotherapy induced nausea and vomiting, CINV, has been a significant problem with oncology patients over past years. As a result much research was done and has lead to the creation of Zofran (Bernstein and Ong 2002). Ondansetron, marketed as Zofran was the first of its kind; it is a serotonin 5-HT3 receptor blocker, otherwise know as an antiemetic agent. Ondansetron is a tremendous breakthrough and is much more effective than older antiemetics, in some cases by almost 50% (Ramsook 2002). Ondansetron was FDA approved in January 1991 as a treatment for chemotherapy-induced nausea and vomiting with parenteraly administered dosage. It was later approved in oral dosage forms as a treatment for post-operative nausea and vomiting in April 1995. In 1999 ondansetron was approved for use as an "orally disintegrating tablet," Zofran ODT®. This form of ondansetron does not require water to assist in swallowing (Clinical Pharmacology 2002). Now ondansetron is used primarily as a treatment for chemotherapy-induce and post-operative nausea and vomiting; however, it is also being recently used to treat drug dependencies such as alcoholism and to treat gastrointestinal disorders such as acute gastroenteritis.
. . .
Some common words found in the essay are:
Acute Gastroenteritis, Clinical Pharmacology, Dr Harris, Desk Reference, Web MD, Bernard Lakoski, Bernstein Ong, Ondansetron FDA, , CINV Harris, serotonin 5-ht3, nausea vomiting, drinks day, emesis obtained, serious effects, incidences emesis, acute gastroenteritis, 5-ht3 receptors, fda approved, 5-ht3 receptor, desk reference 1993, release serotonin 5-ht3, post-operative nausea vomiting, bernstein ong 2002, central nervous system,
Approximate Word count = 1459
Approximate Pages = 6 (250 words per page double spaced)
|
